Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK

Authors: Wei, Jia ;

Matthews, Philippa C.;

Stoesser, Nicole;

Newton, John N.;

Diamond, Ian;

Studley, Ruth;

Taylor, Nick;

Bell, John I.;

Farrar, Jeremy;

Kolenchery, Jaison;

Marsden, Brian D.;

Hoosdally, Sarah;

Jones, E. Yvonne;

Stuart, David I.;

Crook, Derrick W. ;

Peto, Timothy E.A.;

Walker, A. Sarah;

Pouwels, Koen B. ;

Eyre, David W. ;

COVID-19 Infection Survey team

Source: Nature Communications

Full text

: https://doi.org/10.1038/s41467-023-38275-1

Abstract

Following primary SARS-CoV-2 vaccination, whether boosters or breakthrough infections provide greater protection against SARS-CoV-2 infection is incompletely understood. Here we investigated SARS-CoV-2 antibody correlates of protection against new Omicron BA.4/5 (re-)infections and anti-spike IgG antibody trajectories after a third/booster vaccination or breakthrough infection following second vaccination in 154,149 adults ≥18 y from the United Kingdom general population. Higher antibody levels were associated with increased protection against Omicron BA.4/5 infection and breakthrough infections were associated with higher levels of protection at any given antibody level than boosters. Breakthrough infections generated similar antibody levels to boosters, and the subsequent antibody declines were slightly slower than after boosters. Together our findings show breakthrough infection provides longer-lasting protection against further infections than booster vaccinations. Our findings, considered alongside the risks of severe infection and long-term consequences of infection, have important implications for vaccine policy.

Rights

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Cite as

Wei, J., Matthews, P., Stoesser, N., Newton, J., Diamond, I., Studley, R., Taylor, N., Bell, J., Farrar, J., Kolenchery, J., Marsden, B., Hoosdally, S., Jones, E., Stuart, D., Crook, D., Peto, T., Walker, A., Pouwels, K., Eyre, D. & team, C. 2023, 'Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK', Nature Communications, 14, article no: 2799. https://doi.org/10.1038/s41467-023-38275-1

Downloadable citations

HTML BIB RIS

Identifiers

DOI: https://doi.org/10.1038/s41467-023-38275-1